Noteworthy, preclinical approaches are, for example, packaging of IL-2 together with an inhibitor of TGF-β1 in nanoscale liposomal polymeric particles [13], pH-dependent release of IL-12 in the tumor bed to polarize macrophages from M2- to M1-type [14], therapeutic delivery of nanoparticular RNA-lipoplexes (RNA-LPXs) encoding IL-12 in a MYC oncogene-driven murine liver cancer [15], and protein nanogel-enhanced delivery of T cell activating IL-15 in a murine melanoma model and in a humanized glioblastoma mouse model treated with human CAR T cells [16]. The gene discussed is IL2; the disease is neoplasm.